Personalized Medicine Brings Changes

The quickly developing field of personalized medicine is changing diagnostics, treatment and the interplay between the two. This creates challenges for the Food and Drug Administration, which regulates diagnostic tests and drugs quite differently. Could it also mean a change in the economic balance of power between drug and diagnostics companies? I recently covered a Wharton School discussion on the topic for Penn’s LDI Health Economist. — Dinah Wisenberg Brin

 

On Nurse-Patient Ratios

My first published story for the LDI Health Economist, the new online magazine of Penn’s Leonard Davis Institute of Health Economics, explores the nurse-to-patient-ratio issue and research showing that other factors also influence quality of care and nurses’ job satisfaction.